Taicang-based Connect Biopharmaceuticals [Photo/WeChat account: tcfbgw]

The 2020 Suzhou Conference on the Development of Unicorn Enterprise took place on June 18, with Taicang-based Connect Biopharmaceuticals (Connect) shortlisted as a unicorn.

A unicorn is a startup that enjoys a valuation of $1 billion or more. In recent years, unicorns have been highly regarded by the global capital market.

Connect's edges

Connect is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation.

Connect leverages its expertise in the biology of T-cell modulation to build a strong portfolio of innovative product candidates consisting of small molecules and antibodies targeting critical pathways of inflammation.

It is committed to improving the lives of patients in China and around the world by creating novel medicines with better efficacy and fewer side effects.

Taicang-based Connect Biopharmaceuticals [Photo/WeChat account: tcfbgw]

Contact the company

Tel/Fax: +86 0512-53577866

E-Mail: swlu@connectpharm.com

Add: 3rd Floor, East R&D Building, Science and Technology Park, 6 Beijing West Road

Incubation strategy

Since this year, Taicang's science and technology bureau has been doubling down on incubating startups with policy support and improved services to meet the goal of having 1,000 high-tech companies by 2022.

The bureau has increased subsidies for high-tech companies and expanded the application eligibility. The city has received applications from around 800 enterprises so far this year, up 55 percent year on year.